107 related articles for article (PubMed ID: 12521208)
1. Progression of renal failure delayed by use of losartan in a case of IgA nephropathy.
Iseki K; Takishita S
Intern Med; 2002 Dec; 41(12):1167-70. PubMed ID: 12521208
[TBL] [Abstract][Full Text] [Related]
2. Combined therapy of enalapril and losartan attenuates histologic progression in immunoglobulin A nephropathy.
Tanaka H; Suzuki K; Nakahata T; Tsugawa K; Konno Y; Tsuruga K; Ito E; Waga S
Pediatr Int; 2004 Oct; 46(5):576-9. PubMed ID: 15491387
[TBL] [Abstract][Full Text] [Related]
3. A five-year comparison of the renal protective effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with non-diabetic nephropathy.
Shoda J; Kanno Y; Suzuki H
Intern Med; 2006; 45(4):193-8. PubMed ID: 16543688
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of mizoribine combined with losartan in the treatment of IgA nephropathy: a multicenter, randomized, controlled study.
Xie Y; Huang S; Wang L; Miao L; Zhang A; Li Y; Wu X; Wang L; Liu S; Lie C; Chen P; Chen X
Am J Med Sci; 2011 May; 341(5):367-72. PubMed ID: 21293249
[TBL] [Abstract][Full Text] [Related]
5. Effect of angiotensin II receptor blockade on renal disease progression in patients with non-diabetic chronic renal failure.
Mora-Macía J; Cases A; Calero F; Barceló P
Nephrol Dial Transplant; 2001; 16 Suppl 1():82-4. PubMed ID: 11369829
[TBL] [Abstract][Full Text] [Related]
6. Renoprotective effect of small doses of losartan and enalapril in patients with primary glomerulonephritis. Short-term observation.
Tylicki L; Rutkowski P; Renke M; Rutkowski B
Am J Nephrol; 2002; 22(4):356-62. PubMed ID: 12169868
[TBL] [Abstract][Full Text] [Related]
7. Add-on angiotensin receptor blockade with maximized ACE inhibition.
Agarwal R
Kidney Int; 2001 Jun; 59(6):2282-9. PubMed ID: 11380832
[TBL] [Abstract][Full Text] [Related]
8. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
Brenner BM; Cooper ME; de Zeeuw D; Keane WF; Mitch WE; Parving HH; Remuzzi G; Snapinn SM; Zhang Z; Shahinfar S;
N Engl J Med; 2001 Sep; 345(12):861-9. PubMed ID: 11565518
[TBL] [Abstract][Full Text] [Related]
9. Losartan, an angiotensin-II receptor antagonist, retards the progression of advanced renal insufficiency.
Osawa H; Nakamura N; Shirato K; Nakamura M; Shimada M; Kumasaka R; Murakami R; Fujita T; Yamabe H; Okumura K
Tohoku J Exp Med; 2006 May; 209(1):7-13. PubMed ID: 16636517
[TBL] [Abstract][Full Text] [Related]
10. Valsartan combined with clopidogrel and/or leflunomide for the treatment of progressive immunoglobulin A nephropathy.
Cheng G; Liu D; Margetts P; Liu L; Zhao Z; Liu Z; Tang L; Fang Y; Li H; Guo Y; Chen F; Liu F
Nephrology (Carlton); 2015 Feb; 20(2):77-84. PubMed ID: 25358874
[TBL] [Abstract][Full Text] [Related]
11. Hong Kong study using valsartan in IgA nephropathy (HKVIN): a double-blind, randomized, placebo-controlled study.
Li PK; Leung CB; Chow KM; Cheng YL; Fung SK; Mak SK; Tang AW; Wong TY; Yung CY; Yung JC; Yu AW; Szeto CC;
Am J Kidney Dis; 2006 May; 47(5):751-60. PubMed ID: 16632013
[TBL] [Abstract][Full Text] [Related]
12. Estimated GFR decline as a surrogate end point for kidney failure: a post hoc analysis from the Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan (RENAAL) study and Irbesartan Diabetic Nephropathy Trial (IDNT).
Lambers Heerspink HJ; Weldegiorgis M; Inker LA; Gansevoort R; Parving HH; Dwyer JP; Mondal H; Coresh J; Greene T; Levey AS; de Zeeuw D
Am J Kidney Dis; 2014 Feb; 63(2):244-50. PubMed ID: 24210590
[TBL] [Abstract][Full Text] [Related]
13. Comparison of steroids and angiotensin receptor blockers for patients with advanced IgA nephropathy and impaired renal function.
Moriyama T; Amemiya N; Ochi A; Tsuruta Y; Shimizu A; Itabashi M; Takei T; Uchida K; Nitta K
Am J Nephrol; 2011; 34(3):233-40. PubMed ID: 21778707
[TBL] [Abstract][Full Text] [Related]
14. Effect of losartan and amlodipine on proteinuria and transforming growth factor-beta1 in patients with IgA nephropathy.
Park HC; Xu ZG; Choi S; Goo YS; Kang SW; Choi KH; Ha SK; Lee HY; Han DS
Nephrol Dial Transplant; 2003 Jun; 18(6):1115-21. PubMed ID: 12748343
[TBL] [Abstract][Full Text] [Related]
15. Effects of angiotensin II blockade on nitric oxide blood levels in IgA nephropathy.
Roccatello D; Mengozzi G; Gigliola G; Rossi D; Mosso R; Cacace G; Polloni R; Cesano G; Picciotto G; Paradisi L; Bancale E; Piccoli G; Sena LM
Nephrol Dial Transplant; 2000 Jul; 15(7):988-93. PubMed ID: 10862636
[TBL] [Abstract][Full Text] [Related]
16. ACE inhibition or angiotensin receptor blockade: impact on potassium in renal failure. VAL-K Study Group.
Bakris GL; Siomos M; Richardson D; Janssen I; Bolton WK; Hebert L; Agarwal R; Catanzaro D
Kidney Int; 2000 Nov; 58(5):2084-92. PubMed ID: 11044229
[TBL] [Abstract][Full Text] [Related]
17. First-year GFR slope and long-term renal outcome in IgA nephropathy.
Lee K; Shin J; Park J; Hwang S; Jang HR; Huh W; Kwon GY; Kim YG; Oh HY; Lee JE; Kim DJ
Eur J Clin Invest; 2018 Jun; 48(6):e12936. PubMed ID: 29660832
[TBL] [Abstract][Full Text] [Related]
18. Advanced IgA nephropathy with impaired renal function benefits from losartan treatment in rats.
Wang H; Fu W; Jin Z; Wang Y; Yao W; Yin P; Peng W
Ren Fail; 2013 Jul; 35(6):812-8. PubMed ID: 23751143
[TBL] [Abstract][Full Text] [Related]
19. Treatment of IgA nephropathy.
Pozzi C
J Nephrol; 2016 Feb; 29(1):21-5. PubMed ID: 26577268
[TBL] [Abstract][Full Text] [Related]
20. Proinflammatory effects of oxidative stress in chronic kidney disease: role of additional angiotensin II blockade.
Agarwal R
Am J Physiol Renal Physiol; 2003 Apr; 284(4):F863-9. PubMed ID: 12505865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
